Oxford University declared covid-19 vaccine safe and effective

The vaccine developed to prevent coronavirus at Oxford University in the UK is safe and effective.

 This was stated in the vaccine data published in the medical journal The Lancet. 

Most of the people who took part in this data were under the age of 55, but the results indicate that it will work for the elderly. 

According to the data, it will reduce the spread of vaccine code as well as protect against disease and death. The data was analyzed by scientists who had no affiliation with Oxford University or AstraZeneca and involved more than 20,000 people in the trial. 

The same data is being reviewed by the UK's regulatory body and a decision on whether to use or reject it will be made in the next few weeks. 

In late November, Oxford University and the Swedish pharmaceutical company AstraZeneca said the vaccine was 70 to 90 percent effective in preventing the coronavirus. 

According to the trial, the efficacy of the vaccine was 90% in those who took the first half dose and then a few weeks later in the full dose, while in those who took the two full doses the rate was reduced to 62%. 

So the question remains as to which dose would be better to give and which would be safer. 

According to a report published in the Lancet, 1367 out of thousands of people were given first half and then full dose and they got up to 90% protection against code. 

Due to the small number of people, it is difficult to draw any conclusions and researchers have suggested further research in this regard. 

With half the dose, the vaccine is not recommended for people over the age of 55, and older people are at higher risk of developing severe cod. 

As far as its safety is concerned, only the more severe effect of the vaccine at higher temperatures was observed, which is still being investigated. 

"The results show that the vaccine is effective against code 19, the vaccine recipients did not show any serious severity of the disease and no one was admitted to the hospital," said Pascal Soroit, chief executive of AstraZeneca. "

We are in the process of submitting the data to the regulatory authorities around the world so that after the initial approval, we can mobilize the global supply chain, providing millions of doses globally immediately without profit," he said. Will The data comes as Pfizer arrives in the UK on December 8 2020.